TTM
$61.2B
YoY change
+8.6%
5Y CAGR
+17.2%
Peak year (FY2025)
$58.7B
Cumulative revenue
$885B
Revenue history chart for AstraZeneca (AZN) from 2016 to 2025
Latest: $58.7B
Revenue growth chart for AstraZeneca (AZN) from 2016 to 2025
Latest: +8.6%
Revenue history table for AstraZeneca (AZN) from 1990 to 2025
| FY2025 | $58.7B | +8.6% | +$4.67B | ||
| FY2024 | $54.1B | +18.0% | +$8.26B | ||
| FY2023 | $45.8B | +3.3% | +$1.46B | ||
| FY2022 | $44.4B | +18.5% | +$6.93B | ||
| FY2021 | $37.4B | +40.6% | +$10.8B | ||
| FY2020 | $26.6B | +9.2% | +$2.23B | ||
| FY2019 | $24.4B | +10.4% | +$2.29B | ||
| FY2018 | $22.1B | -1.7% | -$375M | ||
| FY2017 | $22.5B | -2.3% | -$537M | ||
| FY2016 | $23B | -6.9% | -$1.71B | ||
| FY2015 | $24.7B | -6.9% | -$1.84B | ||
| FY2014 | $26.5B | +2.9% | +$741M | ||
| FY2013 | $25.8B | -7.7% | -$2.17B | ||
| FY2012 | $28B | -16.7% | -$5.62B | ||
| FY2011 | $33.6B | +1.0% | +$322M | ||
| FY2010 | $33.3B | +1.4% | +$465M | ||
| FY2009 | $32.8B | +3.8% | +$1.2B | ||
| FY2008 | $31.6B | +6.9% | +$2.04B | ||
| FY2007 | $29.6B | +11.6% | +$3.08B | ||
| FY2006 | $26.5B | +10.5% | +$2.53B | ||
| FY2005 | $24B | +11.8% | +$2.52B | ||
| FY2004 | $21.4B | +13.7% | +$2.58B | ||
| FY2003 | $18.8B | +5.6% | +$1.01B | ||
| FY2002 | $17.8B | +8.3% | +$1.36B | ||
| FY2001 | $16.5B | -9.0% | -$1.64B | ||
| FY2000 | $18.1B | +19.7% | +$2.98B | ||
| FY1999 | $15.1B | +33.7% | +$3.82B | ||
| FY1998 | $11.3B | +31.8% | +$2.73B | ||
| FY1997 | $8.59B | -6.5% | -$598M | ||
| FY1996 | $9.18B | +21.3% | +$1.62B | ||
| FY1995 | $7.57B | +8.1% | +$564M | ||
| FY1994 | $7B | +6.6% | +$436M | ||
| FY1993 | $6.57B | +8.8% | +$533M | ||
| FY1992 | $6.03B | -17.9% | -$1.32B | ||
| FY1991 | $7.35B | +0.0% | +$2.64M | ||
| FY1990 | $7.35B | — | — |
- FY2025$58.7B+8.6%
- FY2024$54.1B+18.0%
- FY2023$45.8B+3.3%
- FY2022$44.4B+18.5%
- FY2021$37.4B+40.6%
- FY2020$26.6B+9.2%
- FY2019$24.4B+10.4%
- FY2018$22.1B-1.7%
- FY2017$22.5B-2.3%
- FY2016$23B-6.9%
- FY2015$24.7B-6.9%
- FY2014$26.5B+2.9%
- FY2013$25.8B-7.7%
- FY2012$28B-16.7%
- FY2011$33.6B+1.0%
- FY2010$33.3B+1.4%
- FY2009$32.8B+3.8%
- FY2008$31.6B+6.9%
- FY2007$29.6B+11.6%
- FY2006$26.5B+10.5%
- FY2005$24B+11.8%
- FY2004$21.4B+13.7%
- FY2003$18.8B+5.6%
- FY2002$17.8B+8.3%
- FY2001$16.5B-9.0%
- FY2000$18.1B+19.7%
- FY1999$15.1B+33.7%
- FY1998$11.3B+31.8%
- FY1997$8.59B-6.5%
- FY1996$9.18B+21.3%
- FY1995$7.57B+8.1%
- FY1994$7B+6.6%
- FY1993$6.57B+8.8%
- FY1992$6.03B-17.9%
- FY1991$7.35B+0.0%
- FY1990$7.35B—
Revenue values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Revenue at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current revenue (TTM) is $61.2B. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, AstraZeneca (AZN) reported revenue of $58.7B – grew 8.6% year-over-year.
Across 2020–2025 (5 years), AstraZeneca revenue produced a CAGR of +17.2% – sustaining 7 straight years of year-over-year growth.
2025 marks the peak revenue at $58.7B, with the historical low of $6.03B recorded in 1992.
AstraZeneca Revenue by Year
AstraZeneca Revenue 2025: $58.7B
AstraZeneca revenue in 2025 was $58.7B, grew 8.6% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Revenue 2024: $54.1B
2024's revenue for AstraZeneca came in at $54.1B, grew 18.0% from 2023.
AstraZeneca Revenue 2023: $45.8B
AstraZeneca posted revenue of $45.8B in 2023, edged up 3.3% from 2022.
AstraZeneca Revenue 2022: $44.4B
In 2022, AstraZeneca reported revenue of $44.4B, grew 18.5% from 2021.
AstraZeneca Revenue 2021: $37.4B
AstraZeneca revenue in 2021 was $37.4B.
See more financial history for AstraZeneca (AZN).
Sector peers by Revenue
Healthcare peers of AstraZeneca (AZN), ranked by their latest revenue
| $448B | |
| $94.2B | |
| $65.2B | |
| $64.9B | |
| $61.2B | |
| $48.2B | |
| $44.6B | |
| $36.7B |
- $94.2B
- $65.2B
- $64.9B
- $61.2B
- $48.2B
- $36.7B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.18% TTM
- Dividend Profile1.85% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History3 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.